MedTrace Logo

Effect of Sofosbuvir-daclatasuvir on Angiogenesis

NCT03646396 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-08-24

No results posted yet for this study

Summary

The study aimed at study of the Effect of Daclatasvir Plus Sofosbuvir on Angiogenesis in Egyptian Patients With Chronic HCV Infection

Conditions

  • HCV Coinfection

Interventions

DRUG

Sofosbuvir-daclatasvir

Sofosbuvir-daclatasvir for 3 months

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Eman h abd El-Razek, Msc · Clinical pharmacy Department- Tanta University

  • Tarek M Mostafa, Ph D · Clinical pharmacy Department- Tanta University

  • Nashwa Shebl, Ph D · Hematology and Gastroenterology - Menoufia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2025-08-31
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03646396 on ClinicalTrials.gov